Moderate

Pulmonary hypertension — classification & diagnostic approach

PH group evaluation · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Pulmonary hypertension is a mean pulmonary artery pressure >20 mmHg with diverse causes grouped into five WHO categories. Accurate classification is essential because management diverges sharply — PAH-specific drugs help Group 1 but can harm patients with left-heart or lung disease.

Red flags

  • Syncope on exertion
  • Rapidly progressive right heart failure
  • Resting hypoxaemia
  • Signs of low cardiac output
  • Rapid functional-class deterioration

Assessment

Differential diagnosis

  • Group 1 — pulmonary arterial hypertension
  • Group 2 — left-heart disease (commonest)
  • Group 3 — lung disease/hypoxia
  • Group 4 — chronic thromboembolic (CTEPH)
  • Group 5 — miscellaneous/multifactorial
  • Non-PH causes of breathlessness

Investigations

  • Transthoracic echo to estimate PA pressure and RV function
  • Right-heart catheterisation (gold standard for diagnosis and haemodynamics)
  • V/Q scan to exclude CTEPH
  • Pulmonary function tests and high-resolution CT for lung disease
  • Connective-tissue, HIV and liver screens for PAH associations
  • NT-proBNP and 6-minute walk for risk stratification

Management

  • Confirm raised PA pressure on echocardiography and assess RV function
  • Systematically exclude left-heart disease (Group 2) and lung disease (Group 3)
  • Perform a V/Q scan in all patients to detect CTEPH (Group 4)
  • Confirm precapillary PH and measure pulmonary vascular resistance at right-heart catheterisation
  • Classify into the correct WHO group before any therapy decision
  • Treat the underlying cause in Groups 2 and 3 rather than using PAH drugs
  • Refer Group 1 (PAH) and Group 4 (CTEPH) to a specialist PH centre
  • Risk-stratify PAH using multiparametric tools to guide initial combination therapy
  • Avoid PAH-specific vasodilators in left-heart or significant lung disease
  • Provide supportive care: diuretics, oxygen, supervised rehabilitation
  • Counsel on pregnancy avoidance in PAH
  • Arrange specialist long-term monitoring

Drugs & doses

Treatment is group-specific; PAH drugs are reserved for Group 1/4 in expert centres
Furosemide 20-80 mg PO/IV for right-heart congestion (all groups)
Oxygen therapy for hypoxaemia (Group 3)
Diuretics and GDMT for the underlying left-heart disease (Group 2)
Specialist PAH therapy examples: ambrisentan, tadalafil, selexipag (Group 1 only)

Disposition

Refer confirmed/suspected Group 1 or 4 PH to a specialist pulmonary hypertension centre. Manage Groups 2 and 3 by treating the underlying disease.

Complications & pitfalls

  • Right ventricular failure and death
  • Arrhythmia
  • Harm from inappropriate vasodilator use in Group 2/3
  • Haemoptysis (especially CTEPH)
  • Hepatic congestion

Exam pearls

  • Group 2 (left-heart disease) is by far the most common cause of PH
  • PAH-specific drugs can cause pulmonary oedema if given in left-heart disease
  • A V/Q scan is mandatory to avoid missing curable CTEPH
  • Right-heart catheterisation is required to confirm the diagnosis and class
  • Only expert centres should initiate PAH-targeted therapy

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.